The Architect of Biotech Billions Joins Slate's Migraine Mission

RALEIGH, N.C. – July 15, 2026

In the calculated world of biotechnology, board appointments are rarely just about governance; they are roadmaps. When a company adds a new director, investors and analysts scrutinize the appointee's history not just for experience, but for intent. With its announcement today that Mark W. Hahn will join its Board of Directors, the privately-held Slate Medicines has unfurled a map pointing directly toward significant strategic horizons, be it a public market debut, a major partnership, or an eventual acquisition.

Hahn is not merely an experienced executive; he is a financial architect with a blueprint for transforming private biotechs into highly valued public companies and acquisition targets. His appointment is a clear and powerful signal from Slate and its top-tier investors—RA Capital, Forbion, and Foresite Capital—that the company is preparing for its next phase of high-stakes growth.

"We are pleased to welcome Mark to the Slate Medicines Board at such a pivotal moment for the company," said Gregory Oakes, Slate's Chief Executive Officer. "His history of steering companies through defining financial, clinical and commercial milestones, including transitions from private to public, will be a tremendous asset as Slate works to bring much-needed new treatment options to migraine patients who remain underserved by current therapies."

A Pattern of Billion-Dollar Exits

To understand the significance of Hahn’s arrival, one need only look at his recent track record, which reads like a highlight reel of biotech value creation. Most recently, he served as CFO of Verona Pharma, a company he guided from clinical-stage development to a blockbuster exit. Under his financial stewardship, Verona successfully navigated Phase 3 trials, secured FDA approval for its COPD therapy Ohtuvayre®, and executed a commercial launch that culminated in a staggering $10 billion acquisition by Merck in 2025. Hahn was at the helm, managing the financial strategy that made such a valuation possible.

Before Verona, his tenure at Dova Pharmaceuticals followed a similar, if smaller-scale, trajectory. As CFO, he was instrumental in the company’s growth, which led to its acquisition by Swedish Orphan Biovitrum for up to $915 million. And prior to that, at Cempra, he led the company's initial public offering (IPO) and subsequent financing rounds that raised over half a billion dollars, demonstrating his proficiency in navigating the public markets.

This pattern is unmistakable. Companies bring Mark Hahn on board when they have a promising asset and are ready to build the corporate and financial infrastructure needed for a major liquidity event. His expertise is not just in balancing books, but in constructing the narrative and the numbers that attract public investors and large pharmaceutical acquirers.

A New Frontier in Migraine Therapy

Slate Medicines is not just building a corporate strategy; it is advancing a scientific one. The company’s lead asset, SLTE-1009, aims to carve out a new space in the crowded but underserved migraine market. While the last decade saw a revolution in migraine prevention with the arrival of CGRP (calcitonin gene-related peptide) inhibitors, these treatments were not a panacea. A significant portion of patients either do not respond to CGRP-targeted therapies or suffer from side effects, leaving a persistent unmet need.

Slate is targeting a different but related pathway involving PACAP (pituitary adenylate cyclase-activating polypeptide). This neuropeptide is also implicated in the complex pathophysiology of migraine, and developing an antagonist represents a next-generation approach. By pursuing a potential best-in-class anti-PACAP therapeutic, Slate is betting that a novel mechanism can succeed where others have failed, offering hope to a new segment of the millions who suffer from debilitating headaches.

This scientific ambition is what attracted Hahn. "I'm happy to join Slate Medicines' Board at such an exciting time in the company's continued evolution,” he stated. "PACAP-targeting therapeutics offer a compelling opportunity to expand the treatment paradigm for migraine prevention, and I look forward to helping the team build on its strong financial and scientific foundation to advance SLTE-1009 and the broader pipeline for patients who need new options.”

Bringing a novel drug like SLTE-1009 through late-stage trials, regulatory approval, and commercial launch is a capital-intensive and complex process. Hahn’s experience at Verona—taking Ohtuvayre® across that exact finish line—provides Slate with invaluable firsthand knowledge of the operational and financial hurdles ahead.

The Investor Playbook in Action

Behind Slate Medicines is a consortium of some of the most sophisticated investors in life sciences. RA Capital, Forbion, and Foresite Capital are known for identifying promising science and then actively helping build companies capable of realizing that promise. The appointment of Hahn is a classic move from this investor playbook: once the science is de-risked to a certain point, the focus shifts to de-risking the corporate and financial strategy.

These investors are not just passive sources of capital; they are active partners in value creation. Their involvement suggests a shared belief in the multi-billion-dollar potential of Slate's platform. By adding a director with a proven M&A and IPO track record, they are preparing the company for all potential strategic outcomes. Whether the ultimate goal is to take Slate public on the strength of its clinical data or to position it for a strategic acquisition by a larger pharmaceutical player eager to enter the PACAP space, Hahn is the ideal pilot for the journey.

The Gravitational Pull of Innovation

The move also highlights a broader trend in the life sciences ecosystem: the flow of top-tier, experienced talent toward nimble, privately-held innovators. For an executive like Hahn, who has already reached the pinnacle of financial success within publicly traded companies, the allure of a company like Slate is clear. It offers the chance to shape a company's destiny from a more foundational level, to be intimately involved with groundbreaking science, and to potentially orchestrate another major success story.

This migration of talent from established giants to emerging players is a testament to where the most disruptive innovation is often happening. Smaller biotechs, backed by focused and ambitious venture capital, can often move faster and take on more scientific risk than their larger, more bureaucratic counterparts. For seasoned leaders, this environment offers a powerful blend of challenge, impact, and significant financial upside.

Hahn's decision to join Slate’s board is therefore more than just a new job; it is an endorsement of the company's science, its leadership, and its potential. It validates the belief that this small Raleigh-based company could be the source of the next major breakthrough in headache medicine. For patients, investors, and the industry at large, Slate Medicines has just become a company to watch very closely.